Anthem Biosciences IPO
Anthem Biosciences is a BSE SME IPO is priced at ₹540–₹570 per share with an issue size of ₹3395 crore. The IPO opens on Jul 14, 2025 and closes on Jul 16, 2025, with a lot size of 26 shares and a minimum investment of ₹14,820.
Anthem Biosciences Limited IPO
- IPO Dates
- Jul 14, 2025 – Jul 16, 2025
- Price band
- ₹540-570 per equity share
- Minimum Investment
- ₹14,820
- Issue size
- ₹3395 Cr
- Lot size
- 26
- Allotment Date
- Jul 17, 2025
- Listing
- Jul 21, 2025
- Listing At
- BSE SME
IPO timeline
-
Jul 14, 2025
Open Date
Completed
-
Jul 16, 2025
Close Date
Completed
-
Jul 17, 2025
Allotment Date
Completed
-
Jul 21, 2025
Listing Date
Completed
Anthem Biosciences IPO Expected Premium (Grey Market Trend)
Anthem Biosciences IPO GMP today is ₹105. Grey market premium (GMP) indicates expected listing sentiment.
Anthem Biosciences IPO expected premium (also known as grey market premium or GMP) indicates current market sentiment and potential listing expectations.
Expected Premium provided in this website is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.
Anthem Biosciences IPO Live Subscription Details
View Subscription DetailsAnthem Biosciences IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.
Last updated:Anthem Biosciences IPO Essentials
Anthem Biosciences IPO Details
Anthem Biosciences IPO is priced at ₹540-570 per share with a total issue size of 3395 crore. The IPO has a lot size of 26 shares and will be listed on BSE SME.
- Issue price
- ₹540-570 per equity share
- Lot size
- 26 shares
- Face value
- ₹2 Per Equity Share
- Issue size
- OFS : 5,95,61,404 shares(aggregating up to ₹3395.00 Cr)
- Total issue size
- 5,95,61,404 shares
(aggregating up to ₹3395 crore) - Offer for sale (OFS)
- 5,95,61,404 shares
(aggregating up to ₹3395 crore) - Listing at
- BSE SME
- Listing date
- Registrar
- Kfin Technologies Limited
- Lead manager
-
Jm Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd
Market Lot Size
Investors can bid for a minimum of 26 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 26 | ₹14,820 |
| Retail(max) | 13 | 338 | ₹1,92,660 |
| sHNI(min) | 14 | 364 | ₹2,07,480 |
| sHNI(max) | 67 | 1,742 | ₹9,92,940 |
| sHNI(min) | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences IPO Reservation
Anthem Biosciences IPO reservation details show category-wise allocation of shares. Out of the total 4,493 shares, approximately 0% are reserved for QIB, and 0% for NII.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,124 (NA%) | |
| NII (HNI) Shares Offered | 3,369 (NA%) | |
| Total Shares Offered | 4,493 (NA%) |
Anthem Biosciences IPO Analytics
Anthem Biosciences Valuations
Earnings
- EPS Pre IPO
- ₹8.07/-
- EPS Post IPO
- ₹8.07/-
- P/E Pre IPO
- 70.62
- P/E Post IPO
- 70.62
Returns
- ROE
- 20.82%
- ROCE
- 26.88%
- RoNW
- 20.82%
- PAT Margin
- 23.38%
Fundamentals
- Debt / Equity
- 0.05
- Price / Book
- 13.23
Anthem Biosciences Financials( In Crs.)
| 31-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Revenue | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| Net Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves & Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
Anthem Biosciences Company & Offer Insights
About Anthem Biosciences
Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.
The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.
The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.
Anthem Biosciences Promoter(s)
Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, Ishaan Bhardwaj are the company's promoters of Anthem Biosciences.
Anthem Biosciences IPO Issue Objectives
- •
- The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
Anthem Biosciences IPO - Anchor Investors
Anthem Biosciences IPO: Institutional buyers select Rs 1,016 crore worth of shares through anchor book.
World marquee investors such as Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, Optimix Wholesale Global Emerging Markets Share Trust, PineBridge Global Funds, and Societe Generale acquired the pharma firm's shares through anchor book.
Most asset management firms such as HDFC Mutual Fund, ICICI Prudential AMC, Kotak Mahindra Trustee, Nippon Life India Trustee, Aditya Birla Sun Life AMC, Axis Mutual Fund, Whiteoak Capital Mutual Fund, Franklin, Mirae Asset, UTI MF, Motilal Oswal MF, Quant Mutual Fund, Edelweiss Trusteeship, and Bandhan Mutual Fund also invested the lion's share of money (approximately Rs 604.4 crore) in to Anthem Biosciences through anchor book.
Anthem Biosciences IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Anthem Biosciences | N/A | N/A | 20.8% | 1844 |
| Syngene International | 6.21 | 51.54 | 11.05% | 4642 |
| Sai Life Sciences | 7.45 | 92.18 | 10.96% | 1694 |
| Cohan Lifesciences | 14.11 | 97.29 | 13.61% | 1197 |
| Divi's Lab | 10.24 | 83.22 | 15.35% | 9360 |
Anthem Biosciences IPO - Strengths and Risks
Anthem Biosciences IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Anthem Biosciences
+91 080 6672 400
No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099
Registrar Contact Details
Kfin Technologies Limited
04067162222, 04079611000
Frequently Asked Questions
Click any question to reveal the answer
Anthem Biosciences IPO is a book-built IPO worth ₹3395 crore. The price band is ₹540–₹570 per share. The IPO opens on Jul 14, 2025 and closes on Jul 16, 2025. It will be listed on BSE SME Platform. Kfin Technologies Limited is the registrar.
The price band of Anthem Biosciences IPO is ₹540 to ₹570 per share.
The lot size of Anthem Biosciences IPO is 26 shares.
The minimum investment for Anthem Biosciences IPO is approximately ₹14,820 based on the upper price band .
Anthem Biosciences IPO opens on Jul 14, 2025 and closes on Jul 16, 2025.
The allotment date of Anthem Biosciences IPO is Jul 17, 2025.
Anthem Biosciences IPO is expected to be listed on Jul 21, 2025, on BSE SME Platform.
The Grey Market Premium (GMP) for Anthem Biosciences IPO is ₹105-109 as of Jul 14, 2025. Based on the upper price band of ₹570, the estimated listing price is ₹675, representing a potential gain of approximately 18%.
Anthem Biosciences IPO valuation snapshot: P/E 70.62, EPS ₹8.07/-, P/B 13.23, RoNW 20.82%, and market cap N/A.
To apply for Anthem Biosciences IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Anthem Biosciences IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Anthem Biosciences IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Anthem Biosciences IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Anthem Biosciences IPO allotment status on IPO Ji for quick and easy access.